Source: Nirvana Life Sciences
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
  • The LOI is for the development and distribution of the company’s psilocybin and psilocin based products
  • The strategic relationship will begin with the production of 20g each of psilocybin and psilocin and will increase with market demands
  • INVP is a company dedicated to being a leading service provider in the Health Canada-regulated space by offering a broad range of services
  • Nirvana Life Sciences Inc. a life sciences company with the objective of researching and developing non-addictive pain management and relapse prevention products
  • Shares of Nirvana Life Sciences Inc. are unchanged, trading at $0.47 per share at 09:53 am ET

Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)

The LOI is for the development and distribution of the company’s psilocybin and psilocin based products.

The partnership will begin with the production of 20g each of psilocybin and psilocin and will increase with market demand.

“This is a major step for the company, the ability to develop and distribute unique products through a Health Canada licensed facility that has full analytical capabilities will allow Nirvana to offer the highest level of quality assurance,” noted Michael McCune, Nirvana’s Vice President of Operations.

“Working with Innovate through to development and distribution of our novel addictions focused formulations will ensure that each level of the supply chain can meet the rigorous standards set forth by Health Canada,” he added.

A biotechnology and wellness research centre, INVP is dedicated to being a leading service provider in the Health Canada-regulated space by offering a broad range of services.

These services include analytical testing, research and development (R&D), patentable intellectual property (IP) development and protection, genomic services, pharmaceutical product development which includes novel formulations, manufacturing and more.

Nirvana Life Sciences Inc. a life sciences company with the objective of researching and developing non-addictive pain management and relapse prevention products that mitigate the symptoms of chronic pain and support patients who battle with addiction.

Shares of Nirvana Life Sciences Inc. are unchanged, trading at $0.47 at 09:50 am ET.

More From The Market Herald
Red Light Holland - Partner, Wiz Khalifa.

" Red Light Holland (CSE:TRIP) partners with Wiz Khalifa

Red Light Holland (TRIP) and rapper Wiz Khalifa will launch Mistercap, a new psilocybin brand.

" Psyched Wellness (CSE:PSYC) to remain ‘CALM’ during first pilot production run

Psyched Wellness Ltd. (PSYC) initial pilot production run for its first-to-market AME-1 product, ‘Calm’ is scheduled for July 7.
Red Light Holland - CEO, Todd Shapiro.

" Red Light Holland (CSE:TRIP) updates plan to enter Oregon’s psilocybin market

Red Light Holland (TRIP) has released its updated plan to enter Oregon’s psilocybin market.

" Mindset (CSE:MSET) announces psychedelic drug research collaboration with CAMH

Mindset Pharma (MSET) has announced a research collaboration with the Centre for Addiction and Mental Health (CAMH), a psychiatric research hospital in Toronto.